老年非糖尿病肥胖者持续与最低限度GLP-1 RA暴露的代谢结局比较
本回顾性队列研究纳入以色列Clalit Health Services中65岁及以上、无糖尿病、基线BMI≥30 kg/m²且有配对BMI测量的成人,比较持续与最低限度GLP-1 RA暴露后的代谢变化。持续暴露组BMI分类改善比例更高,HbA1c分类改善更多,新诊断糖尿病发生率更低。
要点
- 持续GLP-1 RA暴露者BMI分类改善比例高于最低暴露者(55% vs. 30%)。
- 持续暴露者糖尿病诊断发生率低于最低暴露者(2.5% vs. 5.3%)。
- 在配对HbA1c亚组中,持续暴露者糖尿病前期转为正常血糖的比例更高(65% vs. 37%)。
核心结论
- 在无糖尿病的老年肥胖成人中,持续GLP-1 RA暴露相比最低暴露与BMI分类和HbA1c分类更大幅度改善及更低的糖尿病发生率相关。
- 这些发现描述的是治疗开始后观察到的变化,不能证明具有因果治疗效应。
研究设计与样本
- 回顾性队列研究,数据来自以色列Clalit Health Services。
- 纳入65岁及以上、无糖尿病、基线BMI≥30 kg/m²且有配对BMI测量的成人。
- 按GLP-1 RA配药次数分组:最低暴露为1–2次,持续暴露为≥3次。
主要发现
- 共纳入13 387例患者,69%为女性;持续暴露组11 121例(83%),最低暴露组2266例(17%)。
- BMI分类改善比例:持续暴露组55%,最低暴露组30%(p<0.001);BMI中位变化分别为−8%和−2%。
- 在7392例有配对HbA1c的患者中,HbA1c改善比例持续组为34%,最低组为20%(p<0.001)。
- 糖尿病前期转为正常血糖的比例:持续组65%,最低组37%。
- 新诊断糖尿病发生率:持续组2.5%,最低组5.3%(p<0.001)。
关键数值与推荐
- 校正年龄、性别、社会经济状况和合并症后,持续暴露与BMI改善相关(OR:2.77,95% CI:2.51–3.06)。
临床怎么用
- 对于无糖尿病的老年肥胖患者,持续使用GLP-1 RA可能在体重和血糖代谢方面带来更有利的变化。
局限性
- 回顾性观察设计,不能排除未测量的混杂因素。
- 结论仅反映治疗开始后的观察变化,不能证明因果治疗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims To compare changes in body mass index (BMI) categories after sustained versus minimal glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposure in older adults with obesity and without diabetes. A secondary aim was to compare changes in glycated haemoglobin (HbA1c) categories among those with paired HbA1c measurements. Materials and Methods Retrospective cohort study within Clalit Health Services, Israel. Adults aged ≥ 65 years without diabetes, with baseline BMI ≥ 30 kg/m2 and paired BMI measurements, were classified as minimal (1–2 dispensations) or sustained (≥ 3) exposure. The primary outcome was BMI category improvement. Secondary outcomes were relative BMI change, HbA1c category change in the paired-HbA1c subset, and incident diagnosed diabetes. BMI improvement was modelled by logistic regression adjusted for age, sex, socioeconomic status and comorbidity. Results Of 13 387 patients (69% female), 11 121 (83%) had sustained and 2266 (17%) minimal exposure. BMI category improved in 55% of the sustained versus 30% of the minimal group (p < 0.001; median change −8% vs. −2%). Among 7392 with paired HbA1c, HbA1c improved in 34% versus 20% (sustained vs. minimal; p < 0.001), and 65% versus 37% of those with prediabetes became normoglycaemic. Diabetes diagnosis was less frequent with sustained exposure (2.5% vs. 5.3%; p < 0.001). Adjusted for measured confounders, sustained exposure was associated with BMI improvement (OR: 2.77, 95% CI: 2.51–3.06). Conclusions Among older adults with obesity and without diabetes, sustained versus minimal GLP-1 RA exposure was associated with greater improvement in BMI and HbA1c categories and a lower incidence of diabetes. These findings describe observed changes after treatment initiation, not a proven causal treatment effect.
引用
- Diabetes, Obesity and Metabolism:Sustained Versus Minimal GLP‐1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。